Table 1. Number of CpG sites significantly associated with at least one proximal SNP.
| R2 | All sites | Q1 (0–2.1%) | Q2 (2.1–4.7%) | Q3 (4.7–10.9%) | Q4 (10.9–21.4%) | Q5 (21.4–100%) |
|---|---|---|---|---|---|---|
| 2–5% | 19,216 | 769 | 1,775 | 3,521 | 5,920 | 7,229 |
| 5–10% | 14,494 | 355 | 951 | 2,234 | 4,508 | 6,444 |
| 10–25% | 12,284 | 164 | 515 | 1,498 | 3,490 | 6,616 |
| 25–50% | 4,960 | 22 | 89 | 370 | 1,133 | 3,345 |
| 50–75% | 1,416 | 2 | 5 | 30 | 225 | 1,154 |
| 75%+ | 338 | 0 | 0 | 1 | 8 | 329 |
| Total | 52,708 | 1,312 | 3,335 | 7,654 | 15,284 | 25,117 |
SNP, single-nucleotide polymorphism.
Counts are stratified based on the site’s inter-individual variability and R2-value (proportion of methylation variance explained) between the SNP and CpG pairs. The variability of a site is measured as its 95%-reference range (the difference between the most and least methylated individuals, among 95% of the individuals forming the central distribution of methylation values) stratified in quintiles (Q1–Q5); percentages in brackets indicate the corresponding 95%-reference range values.